查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1417424

代謝型麩胺酸受體的全球市場：趨勢、預測與競爭分析（~2030 年）

Metabotropic Glutamate Receptor Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 - page report | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

代謝型麩胺酸受體的趨勢與預測

預計到 2030 年，全球代謝型麩胺酸受體市場規模將達到 23 億美元，2024 年至 2030 年複合年成長率為 11.0%。該市場的主要促進因素是神經系統疾病盛行率的增加、可支配收入的增加以及全球老年人口的成長。代謝型麩胺酸受體的全球市場前景廣闊，注意力不足過動症（ADHD）、阿茲海默症和慢性阻塞性肺病（COPD）市場充滿機會。

代謝型麩胺酸受體市場洞察

Lucintel 預測 mGlur5 在預測期內將經歷最高成長。

由於該地區擁有完善的醫療基礎設施、不斷增加的研究經費以及大量患有神經系統疾病的患者，預計北美在預測期內將出現最高的成長。

常問問題

Q.1 代謝型麩胺酸受體的市場規模有多大？

A1. 到 2030 年，全球代謝型麩胺酸受體市場預計將達到 23 億美元。

Q.2 代謝型麩胺酸受體市場的成長預測是多少？

A2. 2024年至2030年，全球代謝型麩胺酸受體市場預計將以11.0%的複合年成長率成長。

Q.3 影響代謝型麩胺酸受體市場成長的關鍵促進因素有哪些？

A3. 該市場的主要促進因素是神經系統疾病盛行率的增加、可支配收入的增加以及全球老年人口的增加。

Q4.市場的主要細分市場是什麼？

A4. 由於注意力不足過動症（ADHD）、阿茲海默症和慢性阻塞性肺病（COPD）市場的機遇，全球代謝型麩胺酸受體市場的未來看起來充滿希望。

Q5.市場上主要企業有哪些？

A5. 主要代謝型麩胺酸受體公司如下。

  • Eli Lilly and Company
  • Novartis International
  • Prexton Therapeutics
  • Addex Therapeutics
  • Taisho Pharmaceutical Holding
  • Astrazeneca
  • Domain Therapeutic
  • Abcam
  • Johnson & Johnson
  • Medgenic

Q6.未來最大的細分市場是什麼？

A6.Lucintel 預計 mGlur5 在預測期內將達到最高成長。

Q7. 未來五年預計哪個地區將成為最大的市場？

A7. 由於該地區擁有完善的醫療基礎設施、不斷增加的研究經費以及大量受神經系統疾病影響的患者，預計北美在預測期內將出現最高的成長。

Q8. 可以客製化報告嗎？

A8. 是的，Lucintel 提供 10% 的客製化服務，無需額外付費。

目錄

第1章執行摘要

第2章全球代謝型麩胺酸受體市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與挑戰

第3章 2018-2030年市場趨勢與預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 全球代謝型麩胺酸受體市場趨勢（2018-2023）與預測（2024-2030）
  • 全球代謝型麩胺酸受體市場：依產品類型
    • mGluR2
    • mGluR4
    • mGluR5
  • 全球代謝型麩胺酸受體市場：依應用分類
    • 注意力不足過動症（ADHD）
    • 阿茲海默症
    • 慢性阻塞性肺病（COPD）

第4章市場趨勢與預測分析：按地區（2018-2030）

  • 全球代謝型麩胺酸受體市場：按地區
  • 北美洲
  • 歐洲
  • 亞太地區
  • 其他地區

第5章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
    • 依產品類型
    • 按用途
    • 按地區
  • 全球代謝型麩胺酸受體市場的新趨勢
  • 戰略分析
    • 新產品開發
    • 擴大全球代謝型麩胺酸受體市場的產能
    • 全球代謝型麩胺酸受體市場的合併、收購與合資企業
    • 認證和許可

第7章主要企業概況

  • Eli Lilly and Company
  • Novartis International
  • Prexton Therapeutics
  • Addex Therapeutics
  • Taisho Pharmaceutical Holding
  • Astrazeneca
  • Domain Therapeutic
  • Abcam
  • Johnson & Johnson
  • Medgenic
簡介目錄

Metabotropic Glutamate Receptor Trends and Forecast

The future of the global metabotropic glutamate receptor market looks promising with opportunities in the attention deficit hyperactivity disorder (ADHD), alzheimer's disease, and chronic obstructive pulmonary disease (COPD) markets. The global metabotropic glutamate receptor market is expected to reach an estimated $2.3 billion by 2030 with a CAGR of 11.0% from 2024 to 2030. The major drivers for this market are increase in the prevalence of neurological conditions, growth in disposable income and rise in the world's elderly population.

A more than 150-page report is developed to help in your business decisions.

Metabotropic Glutamate Receptor by Segment

The study includes a forecast for the global metabotropic glutamate receptor by product type, application, and region.

Metabotropic Glutamate Receptor Market by Product Type [Shipment Analysis by Value from 2018 to 2030]:

  • mGluR2
  • mGluR4
  • mGluR5

Metabotropic Glutamate Receptor Market by Application [Shipment Analysis by Value from 2018 to 2030]:

  • Attention Deficit Hyperactivity Disorder
  • Alzheimer's Disease
  • Chronic Obstructive Pulmonary Disease

Metabotropic Glutamate Receptor Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • Europe
  • Asia Pacific
  • ROW

List of Metabotropic Glutamate Receptor Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies metabotropic glutamate receptor companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the metabotropic glutamate receptor companies profiled in this report include-

  • Eli Lilly and Company
  • Novartis International
  • Prexton Therapeutics
  • Addex Therapeutics
  • Taisho Pharmaceutical Holding
  • Astrazeneca
  • Domain Therapeutic
  • Abcam
  • Johnson & Johnson
  • Medgenic

Metabotropic Glutamate Receptor Market Insights

Lucintel forecasts that mGlur5 is expected to witness highest growth over the forecast period.

North America is expected to witness highest growth over the forecast period due to existence of well-established healthcare infrastructure, rise in research funding, huge patient pool suffering from neurological disorders in the region.

Features of the Global Metabotropic Glutamate Receptor Market

Market Size Estimates: Metabotropic glutamate receptor market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Metabotropic glutamate receptor market size by product type, application, and region in terms of value ($B).

Regional Analysis: Metabotropic glutamate receptor market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different product type, application, and regions for the metabotropic glutamate receptor market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the metabotropic glutamate receptor market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1 What is the metabotropic glutamate receptor market size?

Answer: The global metabotropic glutamate receptor market is expected to reach an estimated $2.3 billion by 2030.

Q.2 What is the growth forecast for metabotropic glutamate receptor market?

Answer: The global metabotropic glutamate receptor market is expected to grow with a CAGR of 11.0% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the metabotropic glutamate receptor market?

Answer: The major drivers for this market are increase in the prevalence of neurological conditions, growth in disposable income and rise in the world's elderly population.

Q4. What are the major segments for metabotropic glutamate receptor market?

Answer: The future of the global metabotropic glutamate receptor market looks promising with opportunities in the attention deficit hyperactivity disorder (ADHD), alzheimer's disease, and chronic obstructive pulmonary disease (COPD) markets.

Q5. Who are the key metabotropic glutamate receptor market companies?

Answer: Some of the key metabotropic glutamate receptor companies are as follows.

  • Eli Lilly and Company
  • Novartis International
  • Prexton Therapeutics
  • Addex Therapeutics
  • Taisho Pharmaceutical Holding
  • Astrazeneca
  • Domain Therapeutic
  • Abcam
  • Johnson & Johnson
  • Medgenic

Q6. Which metabotropic glutamate receptor market segment will be the largest in future?

Answer: Lucintel forecasts that mGlur5 is expected to witness highest growth over the forecast period.

Q7. In metabotropic glutamate receptor market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness highest growth over the forecast period due to existence of well-established healthcare infrastructure, rise in research funding, huge patient pool suffering from neurological disorders in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the metabotropic glutamate receptor market by product type (mGlur2, mGlur4, and mGlur5), application (attention deficit hyperactivity disorder, alzheimer's disease, and chronic obstructive pulmonary disease), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Metabotropic Glutamate Receptor Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Metabotropic Glutamate Receptor Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Metabotropic Glutamate Receptor Market by Product Type
    • 3.3.1: mGluR2
    • 3.3.2: mGluR4
    • 3.3.3: mGluR5
  • 3.4: Global Metabotropic Glutamate Receptor Market by Application
    • 3.4.1: Attention Deficit Hyperactivity Disorder (ADHD)
    • 3.4.2: Alzheimer's Disease
    • 3.4.3: Chronic Obstructive Pulmonary Disease (COPD)

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Metabotropic Glutamate Receptor Market by Region
  • 4.2: North American Metabotropic Glutamate Receptor Market
    • 4.2.2: North American Metabotropic Glutamate Receptor Market by Application: Attention Deficit Hyperactivity Disorder, Alzheimer's Disease, and Chronic Obstructive Pulmonary Disease
  • 4.3: European Metabotropic Glutamate Receptor Market
    • 4.3.1: European Metabotropic Glutamate Receptor Market by Product Type: mGluR2, mGluR4, and mGluR5
    • 4.3.2: European Metabotropic Glutamate Receptor Market by Application: Attention Deficit Hyperactivity Disorder, Alzheimer's Disease, and Chronic Obstructive Pulmonary Disease
  • 4.4: APAC Metabotropic Glutamate Receptor Market
    • 4.4.1: APAC Metabotropic Glutamate Receptor Market by Product Type: mGluR2, mGluR4, and mGluR5
    • 4.4.2: APAC Metabotropic Glutamate Receptor Market by Application: Attention Deficit Hyperactivity Disorder, Alzheimer's Disease, and Chronic Obstructive Pulmonary Disease
  • 4.5: ROW Metabotropic Glutamate Receptor Market
    • 4.5.1: ROW Metabotropic Glutamate Receptor Market by Product Type: mGluR2, mGluR4, and mGluR5
    • 4.5.2: ROW Metabotropic Glutamate Receptor Market by Application: Attention Deficit Hyperactivity Disorder, Alzheimer's Disease,and Chronic Obstructive Pulmonary Disease

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Metabotropic Glutamate Receptor Market by Product Type
    • 6.1.2: Growth Opportunities for the Global Metabotropic Glutamate Receptor Market by Application
    • 6.1.3: Growth Opportunities for the Global Metabotropic Glutamate Receptor Market by Region
  • 6.2: Emerging Trends in the Global Metabotropic Glutamate Receptor Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Metabotropic Glutamate Receptor Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Metabotropic Glutamate Receptor Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Eli Lilly and Company
  • 7.2: Novartis International
  • 7.3: Prexton Therapeutics
  • 7.4: Addex Therapeutics
  • 7.5: Taisho Pharmaceutical Holding
  • 7.6: Astrazeneca
  • 7.7: Domain Therapeutic
  • 7.8: Abcam
  • 7.9: Johnson & Johnson
  • 7.10: Medgenic